Effects of Pramipexole combined with Levodopa and Benserazide hydrochloride tablets in treatment of patients with Parkinson's disease
Objective:To observe effects of Pramipexole combined with Levodopa and Benserazide hydrochloride tablets in treatment of patients with Parkinson's disease.Methods:A prospective study was conducted on 152 patients with Parkinson's disease admitted to this hospital from January 2019 to December 2020.They were divided into observation group and control group according to the random number table method,76 cases in each group.The control group was treated with Levodopa and Benserazide hydrochloride tablets,while the observation group was treated with Pramipexole on the basis of that of the control group.Both groups were treated continuously for 12 weeks.The clinical efficacy,the cognitive function[Montreal cognitive assessment(MoCA)]score,the symptoms[unified Parkinson's disease rating scale(UPDRS)]score,the serological indicators[brain-derived neurotrophic factor(BDNF),norepinephrine(NE),5-hydroxytryptamine(5-HT)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.42%(71/76),which was higher than 76.32%(58/76)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the MoCA score of the observation group was higher than that of the control group,the UPDRS score was lower than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of BDNF,NE and 5-HT in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pramipexole combined with Levodopa and Benserazide hydrochloride tablets in the treatment of the patients with Parkinson's disease can improve the total effective rate,the cognitive function scores and the serological indicator levels,and reduce the symptom scores.Moreover,it is superior to single Levodopa and Benserazide hydrochloride tablets treatment.
Parkinson's diseasePramipexoleLevodopa and Benserazide hydrochloride tabletsCognitive functionSymptomSerologyAdverse reaction
万方数据
维普
